| Bioactivity | Zelminemab (AMG-301) is a human monoclonal antibody that inhibits PACAP type I (PAC1) receptor[1]. |
| In Vivo | Zelminemab（10 mg/kg；i.v.；一次）降低 TCC 中的伤害性神经元活动[2]。 Animal Model: |
| Name | Zelminemab |
| CAS | 2225850-33-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Eloisa Rubio-Beltrán, et al. PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain. 2018 Aug 7;19(1):64. [2]. Hoffmann J, et al. PAC-1 receptor antibody modulates nociceptive trigeminal activity in rat. Cephalalgia. 2016;36(1S):141–141. |